PRO trial for elderly, frail patients with a type of lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), a type of blood cancer.
- You are 80 or older, or you are 60–79 and considered frail or not fit for standard treatment.
- Your lymphoma is the non-GCB type (a specific subtype determined by lab tests).
- You have not had any previous treatment for lymphoma (except steroids).
- You have at least one measurable tumor: a lymph node larger than 1.5 cm or an organ tumor larger than 1 cm on scans.
- Your organs (kidneys, liver, blood cells) are working well enough per study tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial tests a new combination of drugs (Pola-ZR2) against a standard combination (ZR2) for older adults with newly diagnosed diffuse large B-cell lymphoma. It aims to see if the new mix is more effective and safe.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This trial tests a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zanubrutinib) as a first treatment for older adults (70+) with a common type of lymphoma called DLBCL. The goal is to see if this approach is effective and well-tolerated without standard chemotherapy.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.